Use of TRAIL in combination with GSK-3 inhibition has relevance to the treatment of pancreatic cancer as these tumors have a high frequency of K-ras and p53 mutations that likely contribute to their resistance to standard agents [27], [28], whereas TRAIL sensitivity is reported to be p53-independent and TRAIL is effective in tumors with inactive p53 [29]. This evidence concerns the gene TNFSF10 and familial pancreatic carcinoma.